LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats

被引：76

作者：

Konieczny, J

Ossowska, K

Wolfarth, S

Pilc, A

机构：

[1] Polish Acad Sci, Inst Pharmacol, Dept Neuropsychopharmacol, PL-31343 Krakow, Poland

[2] Polish Acad Sci, Inst Pharmacol, Dept Neurobiol, PL-31343 Krakow, Poland

来源：

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 1998年 / 358卷 / 04期

关键词：

group II metabotropic receptors; parkinsonism; muscle rigidity;

D O I：

10.1007/PL00005284

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The aim of this study was to examine whether (+)-2-aminobicyclo[3.1.0]-hexane-2,6-dicarboxylate monohydrate (LY354740), a selective agonist of group II metabotropic glutamate receptors, possesses antiparkinsonian properties. Parkinsonian-like muscle rigidity was induced by pretreatment with haloperidol (1 mg/kg i.p.). It was measured as increased resistance developed by the rat's hind leg to passive extension and flexion. LY354740 (5 and 10 mg/kg i.p.) dose-dependently diminished the haloperidol-induced muscle rigidity. The present results suggest that LY354740 counteracts the muscle rigidity in an animal model of parkinsonism.

引用

收藏

页码：500 / 502

页数：3

相关论文

共 10 条

[1] In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats [J].

Battaglia, G ;

Monn, JA ;

Schoepp, DD .

NEUROSCIENCE LETTERS, 1997, 229 (03) :161-164

[2] Pharmacology and functions of metabotropic glutamate receptors [J].

Conn, PJ ;

Pin, JP .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1997, 37 :205-237

[3] LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats [J].

Helton, DR ;

Tizzano, JP ;

Monn, JA ;

Schoepp, DD ;

Kallman, MJ .

NEUROPHARMACOLOGY, 1997, 36 (11-12) :1511-1516

[4]

Helton DR, 1998, J PHARMACOL EXP THER, V284, P651

[5] EXCITATORY AMINO-ACIDS AND THE BASAL GANGLIA - IMPLICATIONS FOR THE THERAPY OF PARKINSONS-DISEASE [J].

KLOCKGETHER, T ;

TURSKI, L .

TRENDS IN NEUROSCIENCES, 1989, 12 (08) :285-286

[6]

LorencKoci E, 1996, EXP BRAIN RES, V109, P268

[7] Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): A potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties [J].

Monn, JA ;

Valli, MJ ;

Massey, SM ;

Wright, RA ;

Salhoff, CR ;

Johnson, BG ;

Howe, T ;

Alt, CA ;

Rhodes, GA ;

Robey, RL ;

Griffey, KR ;

Tizzano, JP ;

Kallman, MJ ;

Helton, DR ;

Schoepp, DD .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (04) :528-537

[8] The role of striatal glutamate receptors in models of Parkinson's disease [J].

Ossowska, K ;

Lorenc-Koci, E ;

Konieczny, J ;

Wolfarth, S .

AMINO ACIDS, 1998, 14 (1-3) :11-15

[9] THE ROLE OF EXCITATORY AMINO-ACIDS IN EXPERIMENTAL-MODELS OF PARKINSONS-DISEASE [J].

OSSOWSKA, K .

JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, 1994, 8 (1-2) :39-71

[10] LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors [J].

Schoepp, DD ;

Johnson, BG ;

Wright, RA ;

Salhoff, CR ;

Mayne, NG ;

Wu, S ;

Cockerham, SL ;

Burnett, JP ;

Belegaje, R ;

Bleakman, D ;

Monn, JA .

NEUROPHARMACOLOGY, 1997, 36 (01) :1-11